Cosmo Pharmaceuticals N.V.

SWX:COPN Stock Report

Market Cap: CHF 1.0b

Cosmo Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Cosmo Pharmaceuticals has a total shareholder equity of €505.4M and total debt of €559.0K, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are €638.3M and €132.9M respectively. Cosmo Pharmaceuticals's EBIT is €86.0M making its interest coverage ratio 154.4. It has cash and short-term investments of €133.4M.

Key information

0.1%

Debt to equity ratio

€559.00k

Debt

Interest coverage ratio154.4x
Cash€133.41m
Equity€505.39m
Total liabilities€132.87m
Total assets€638.25m

Recent financial health updates

Recent updates

Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

May 02
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

May 20
Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

Apr 03
Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Mar 07
When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Financial Position Analysis

Short Term Liabilities: COPN's short term assets (€183.6M) exceed its short term liabilities (€37.9M).

Long Term Liabilities: COPN's short term assets (€183.6M) exceed its long term liabilities (€95.0M).


Debt to Equity History and Analysis

Debt Level: COPN has more cash than its total debt.

Reducing Debt: COPN's debt to equity ratio has reduced from 38.9% to 0.1% over the past 5 years.

Debt Coverage: COPN's debt is well covered by operating cash flow (20988.6%).

Interest Coverage: COPN's interest payments on its debt are well covered by EBIT (154.4x coverage).


Balance Sheet


Discover healthy companies